Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 284

1.

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJ, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Mar 9. doi: 10.1164/rccm.201701-0193OC. [Epub ahead of print]

PMID:
28278391
2.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish.

3.

Prediction of Chronic Obstructive Pulmonary Disease Exacerbation Frequency. Clinical Parameters Are Still Better Than Biomarkers.

Donaldson GC, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Feb 15;195(4):415-416. doi: 10.1164/rccm.201610-2037ED. No abstract available.

PMID:
28199159
4.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar.

PMID:
28182564
5.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.

Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017.

6.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7.

PMID:
28150362
7.

Randomized Double-blind Controlled Trial of Roflumilast at Acute Exacerbations of COPD.

Mackay AJ, Patel AR, Singh R, Sapsford RJ, Donaldson GC, Prasad N, Goehring UM, Nip TK, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Feb 1. doi: 10.1164/rccm.201612-2518LE. [Epub ahead of print] No abstract available.

PMID:
28146642
8.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

PMID:
28128970
9.

The role of complement activation in COPD exacerbation recovery.

Westwood JP, Mackay AJ, Donaldson G, Machin SJ, Wedzicha JA, Scully M.

ERJ Open Res. 2016 Oct 19;2(4). pii: 00027-2016. doi: 10.1183/23120541.00027-2016. eCollection 2016 Oct.

10.

AJRCCM 2017: 100-Year Anniversary.

Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):1. doi: 10.1164/rccm.201612-2411ED. No abstract available.

PMID:
28035855
11.

Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation.

Law M, Sweeting MJ, Donaldson GC, Wedzicha JA.

Pharm Stat. 2016 Dec 14. doi: 10.1002/pst.1798. [Epub ahead of print]

PMID:
27966248
12.

How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FM, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2016 Dec 6. [Epub ahead of print]

PMID:
27922741
13.

Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.

Bewley MA, Belchamber KB, Chana KK, Budd RC, Donaldson G, Wedzicha JA, Brightling CE, Kilty I, Donnelly LE, Barnes PJ, Singh D, Whyte MK, Dockrell DH; COPDMAP..

PLoS One. 2016 Sep 28;11(9):e0163139. doi: 10.1371/journal.pone.0163139. eCollection 2016.

14.

Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?

Rodriguez-Roisin R, Han MK, Vestbo J, Wedzicha JA, Woodruff PG, Martinez FJ.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):17-22. doi: 10.1164/rccm.201607-1376PP. No abstract available.

PMID:
27598473
15.

Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):541-9. doi: 10.1164/rccm.201606-1179PP.

PMID:
27585383
16.

Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators".

Wedzicha JA.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):527-8. doi: 10.1164/rccm.201608-1566ED. No abstract available.

PMID:
27585375
17.

Indacaterol-Glycopyrronium for COPD.

Wedzicha JA, Banerji D, Vogelmeier CF.

N Engl J Med. 2016 Sep 1;375(9):899-900. doi: 10.1056/NEJMc1609305. No abstract available.

18.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators..

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

19.

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.

Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E.

COPD. 2016 Dec;13(6):669-676. Epub 2016 May 9.

20.

Eosinophils as Biomarkers of Chronic Obstructive Pulmonary Disease Exacerbation Risk. Maybe Just for Some?

Wedzicha JA.

Am J Respir Crit Care Med. 2016 May 1;193(9):937-8. doi: 10.1164/rccm.201601-0015ED. No abstract available.

PMID:
27128699

Supplemental Content

Loading ...
Support Center